Petlife Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
There is insufficient data on Petlife Pharmaceuticals's performance over the last few years.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 28 Feb 2018 |
Recent past performance updates
No updates
Recent updates
No updates
In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Petlife Pharmaceuticals has not provided sufficient past data to assess its track record.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.
Show sectionRevenue & Expenses Breakdown
How Petlife Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 28 Feb 18 | 0 | -4 | 2 | 0 |
| 30 Nov 17 | 0 | -5 | 3 | 0 |
| 31 Aug 17 | 0 | -23 | 22 | 0 |
| 31 May 17 | 0 | -25 | 24 | 0 |
| 28 Feb 17 | 0 | -24 | 24 | 0 |
| 30 Nov 16 | 0 | -23 | 23 | 0 |
| 31 Aug 16 | 0 | -4 | 4 | 0 |
| 31 May 16 | 0 | 0 | 0 | 0 |
| 29 Feb 16 | 0 | 0 | 0 | 0 |
| 30 Nov 15 | 0 | -1 | 0 | 0 |
| 31 Aug 15 | 0 | -2 | 2 | 0 |
| 31 May 15 | 0 | -3 | 3 | 0 |
| 28 Feb 15 | 0 | -3 | 3 | 0 |
| 30 Nov 14 | 0 | -3 | 3 | 0 |
| 31 Aug 14 | 0 | -2 | 1 | 0 |
Quality Earnings: Insufficient data to determine if PTLF has high quality earnings.
Growing Profit Margin: Insufficient data to determine if PTLF's profit margins have improved over the past year.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if PTLF's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Insufficient data to compare PTLF's past year earnings growth to its 5-year average.
Earnings vs Industry: Insufficient data to determine if PTLF's earnings growth over the past year exceeded the Pharmaceuticals industry average.
Return on Equity
High ROE: PTLF has a negative Return on Equity (0%), as it is currently unprofitable.